News | June 09, 2023
Cosette Pharmaceuticals acquires Intrarosa from Endoceutics
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
Fully equipped labs with 75-member team set-up and made operational in <100 days
Study efficacy measures will include the expression of dystrophin protein and motor function.
Subscribe To Our Newsletter & Stay Updated
